NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Lipocine shares were on fire after receiving an upgrade and a price target of $21 a share. Shares of DelMar Pharmaceuticals also soared higher despite any news but a report indicated the company has been granted a U.S. patent related to its VAL-083 drug candidate.
RDI Initiates Coverage on:
DelMar Pharmaceuticals, Inc.
Lipocine's shares were on fire in Tuesday trading, closing the day up 16.03% on high volume. The stock traded roughly 5.5 million shares compared to an average of a little under 550,000 shares. The stock was upgraded by Dr. Cathy Reese of Empire Asset Management to "Buy" from "Hold" and was given a $21 price target. Traders were encouraged by her upgrade considering that the stock is down nearly 57% since the FDA's Bone, Reproductive, and Urologic Drugs Advisory Committee voted 6-13 on Tlando's benefit-risk profile. Tlando is an oral product candidate for testosterone replacement therapy. Reese remarked, "We believe that Tlando has a high probability of gaining an approval, whether it is on the PDUFA date or once the blood pressure and collection test tube clinical data is generated and reviewed, which we believe should occur in 2018."
Access RDI’s Lipocine Inc. Research Report at:
DelMar Pharmaceuticals' shares closed up 13.59% yesterday on almost 4.9 million shares traded. The stock was exploding despite any remarkable news from the company but a Benzinga article reported that the company has been granted U.S. patent related to its VAL-083 drug candidate. It was two months ago that DelMar soared 40% when it announced that its lead-product cancer treatment, VAL-083, was granted "Fast Track" designation by the FDA. Interim CEO Saiid Zarrabian stated at the time, "We are enthusiastic about the potential of VAL-083 to offer a meaningful clinical benefit to patients with rGBM and for the opportunity to expedite the regulatory process through the FDA's Fast Track program." The drug is a potential new treatment for a recurrent cancer of the brain and spinal cord called glioblastoma (rGMBM).
Access RDI's DelMar Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.